[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100384830":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":17,"studyPopulation":18,"armGroups":19,"interventions":37,"overallOfficials":43,"centralContacts":60,"locations":66,"responsibleParty":77,"collaborators":13,"id":79,"slug":13,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":80,"sex":86,"minAge":87,"maxAge":13,"enrollmentInfo":88,"targetDuration":91,"studyType":92,"phases":13,"briefSummary":93,"conditions":94,"keywords":99,"overallStatus":69,"whyStopped":13,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"iOMEDICO AG","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Course of treatment (treatment reality)","Documentation of anamnestic data and therapy sequences","2 years per patient",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","PROSPECTIVE","SAPHIR is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of metastatic esophageal, gastric or gastroesophageal junction Cancer in Germany. The registry will follow patients for up to two years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.\n\nHealth-related quality of life (HRQoL) will be evaluated for up to two years.","Adult patients with metastatic (stage IV) esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC), gastric adenocarcinoma (GAC) or gastroesophageal junction adenocarcinoma (GEJAC), requiring palliative systemic first-line therapy.",[20,25,29,33],{"label":21,"type":13,"description":22,"interventionNames":23},"ESCC","250 patients with esophageal squamous cell carcinoma",[24],"Other: Routine care as per site standard",{"label":26,"type":13,"description":27,"interventionNames":28},"GAC","920 patients with gastric adenocarcinoma",[24],{"label":30,"type":13,"description":31,"interventionNames":32},"GEJAC","580 patients with gastroesophageal junction adenocarcinoma",[24],{"label":34,"type":13,"description":35,"interventionNames":36},"EAC","150 patients with esophageal adenocarcinoma",[24],[38],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":13},"OTHER","Routine care as per site standard","Physician's choice according to patient's needs. Routine care as per site standard.",[34,21,26,30],[44,48,51,54,57],{"name":45,"affiliation":46,"role":47},"Tobias Dechow, Prof.","Ravensburg","STUDY_CHAIR",{"name":49,"affiliation":50,"role":47},"Florian Lordick, Prof.","Leipzig",{"name":52,"affiliation":53,"role":47},"Sylvie Lorenzen, Prof.","München",{"name":55,"affiliation":56,"role":47},"Karin Potthoff, Dr.","Freiburg",{"name":58,"affiliation":59,"role":47},"Anke Reinacher-Schick, Prof.","Bochum",[61],{"name":62,"role":63,"phone":64,"phoneExt":13,"email":65},"Adrian Binninger","CONTACT","+49 761 152 42 - 0","info@iomedico.com",[67],{"facility":68,"status":69,"city":70,"state":13,"zip":13,"country":71,"countryCode":72,"cosmosGeoPoint":13,"geoPoint":13,"contacts":73},"Multiple sites, Gemany","RECRUITING","Multiple Locations","Germany","DE",[74],{"name":75,"role":63,"phone":76,"phoneExt":13,"email":65},"iOMEDICO","+49761152420",{"type":78,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100384830",false,"NCT04290806","Registry Platform Gastric\u002FEsophageal Cancer (SAPHIR)","Clinical Research Platform For Molecular Testing, Treatment, Quality Of Life And Outcome Of Patients With Esophageal, Gastric Or Gastroesophageal Junction Cancer Requiring Palliative Systemic Therapy","SAPHIR","Inclusion Criteria:\n\n* Histologically proven stage IV (metastatic) ESCC, EAC, GAC or GEJAC\n* Planned palliative systemic first-line therapy\n* Age \\>= 18 years\n* Signed informed consent (IC)\n\n  * Patients answering questionnaires: IC before first therapy cycle\n  * Patients not answering questionnaires: IC latest 4 weeks after start of first therapy cycle\n\nExclusion Criteria:\n\n* No systemic therapy for ESCC, EAC, GAC or GEJAC","ALL","18 Years",{"count":89,"type":90},1900,"ESTIMATED","2 Years","OBSERVATIONAL","The registry aims to collect and analyse information on the antineoplastic treatment of patients with metastatic esophageal, gastric or gastroesophageal junction cancer, treated in palliative intention in daily routine practice in Germany.",[95,96,97,98],"Esophageal Squamous Cell Carcinoma","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Esophageal Adenocarcinoma",[100,101,102,103,71,104,105],"neoplasms","registry","health services research","epidemiology","palliative treatment","palliative care","2026-01-26",{"date":108,"type":109},"2026-01-28","ACTUAL",{"date":111,"type":109},"2019-12-04",{"date":113,"type":90},"2028-12-31",{"name":5,"class":6},1]